ECSP12011627A - Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st - Google Patents
Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del stInfo
- Publication number
- ECSP12011627A ECSP12011627A EC2012011627A ECSP12011627A ECSP12011627A EC SP12011627 A ECSP12011627 A EC SP12011627A EC 2012011627 A EC2012011627 A EC 2012011627A EC SP12011627 A ECSP12011627 A EC SP12011627A EC SP12011627 A ECSP12011627 A EC SP12011627A
- Authority
- EC
- Ecuador
- Prior art keywords
- elevation
- treatment
- otamixaban
- alteration
- renal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere al uso de éster metílico del ácido (2R,3R)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico o una sal farmacéuticamente aceptable del mismo, para la preparación de un medicamento para su uso en el infarto de miocardio sin elevación del ST, comprendiendo dicho tratamiento administrar una cantidad terapéuticamente eficaz de éster metílico del ácido (2R,3R)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico o una sal farmacéuticamente aceptable del mismo a un paciente humano, de edad avanzada y/o que muestra insuficiencia renal y/o tiene un bajo peso corporal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09290601 | 2009-07-29 | ||
EP10305192 | 2010-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12011627A true ECSP12011627A (es) | 2012-02-29 |
Family
ID=42542846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2012011627A ECSP12011627A (es) | 2009-07-29 | 2012-01-26 | Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st |
Country Status (25)
Country | Link |
---|---|
US (1) | US9492437B2 (es) |
EP (1) | EP2459193A1 (es) |
JP (1) | JP2013500298A (es) |
KR (1) | KR20120038982A (es) |
CN (1) | CN102470128A (es) |
AR (1) | AR077427A1 (es) |
AU (1) | AU2010277725B2 (es) |
BR (1) | BR112012001900A2 (es) |
CA (1) | CA2766533A1 (es) |
CL (1) | CL2012000196A1 (es) |
CO (1) | CO6491041A2 (es) |
CR (1) | CR20110674A (es) |
DO (1) | DOP2012000012A (es) |
EC (1) | ECSP12011627A (es) |
IL (1) | IL217612A (es) |
MA (1) | MA33455B1 (es) |
MX (1) | MX2012000457A (es) |
NI (1) | NI201200008A (es) |
NZ (1) | NZ597957A (es) |
PE (1) | PE20121401A1 (es) |
RU (1) | RU2542455C2 (es) |
SG (1) | SG177772A1 (es) |
TW (1) | TWI463982B (es) |
UY (1) | UY32807A (es) |
WO (1) | WO2011012527A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI551289B (zh) * | 2011-03-29 | 2016-10-01 | 賽諾菲公司 | 具有改良之安定性之奧米沙班調配物 |
EA025572B1 (ru) | 2011-03-29 | 2017-01-30 | Санофи | Лекарственные формы отамиксабана с улучшенной стабильностью |
CN103562183B (zh) | 2011-03-29 | 2015-12-23 | 赛诺菲 | 奥米沙班的苯甲酸盐 |
US9597322B2 (en) | 2012-08-31 | 2017-03-21 | Sanofi | Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9612423B1 (pt) * | 1996-01-02 | 2010-11-30 | composto de n-[(amino-imino-metil ou amino-metil) fenil] propil amidas substituìdas, e, composição farmacêutica. | |
RU2225617C1 (ru) * | 2002-12-16 | 2004-03-10 | Научно-исследовательский институт кардиологии Томского научного центра СО РАМН | Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st |
-
2010
- 2010-07-22 PE PE2012000036A patent/PE20121401A1/es not_active Application Discontinuation
- 2010-07-22 NZ NZ597957A patent/NZ597957A/en not_active IP Right Cessation
- 2010-07-22 WO PCT/EP2010/060615 patent/WO2011012527A1/en active Application Filing
- 2010-07-22 KR KR1020127002078A patent/KR20120038982A/ko not_active Application Discontinuation
- 2010-07-22 JP JP2012522112A patent/JP2013500298A/ja active Pending
- 2010-07-22 BR BR112012001900A patent/BR112012001900A2/pt not_active IP Right Cessation
- 2010-07-22 CN CN2010800323309A patent/CN102470128A/zh active Pending
- 2010-07-22 MX MX2012000457A patent/MX2012000457A/es active IP Right Grant
- 2010-07-22 CA CA2766533A patent/CA2766533A1/en not_active Abandoned
- 2010-07-22 RU RU2012107483/15A patent/RU2542455C2/ru not_active IP Right Cessation
- 2010-07-22 AU AU2010277725A patent/AU2010277725B2/en not_active Ceased
- 2010-07-22 MA MA34566A patent/MA33455B1/fr unknown
- 2010-07-22 EP EP10735284A patent/EP2459193A1/en not_active Withdrawn
- 2010-07-22 US US13/387,639 patent/US9492437B2/en not_active Expired - Fee Related
- 2010-07-22 SG SG2012006110A patent/SG177772A1/en unknown
- 2010-07-27 TW TW099124612A patent/TWI463982B/zh not_active IP Right Cessation
- 2010-07-27 UY UY0001032807A patent/UY32807A/es not_active Application Discontinuation
- 2010-07-27 AR ARP100102707A patent/AR077427A1/es unknown
-
2011
- 2011-12-15 CR CR20110674A patent/CR20110674A/es unknown
-
2012
- 2012-01-12 NI NI201200008A patent/NI201200008A/es unknown
- 2012-01-16 CO CO12005490A patent/CO6491041A2/es not_active Application Discontinuation
- 2012-01-18 IL IL217612A patent/IL217612A/en not_active IP Right Cessation
- 2012-01-19 DO DO2012000012A patent/DOP2012000012A/es unknown
- 2012-01-24 CL CL2012000196A patent/CL2012000196A1/es unknown
- 2012-01-26 EC EC2012011627A patent/ECSP12011627A/es unknown
Also Published As
Publication number | Publication date |
---|---|
NZ597957A (en) | 2014-05-30 |
UY32807A (es) | 2011-02-28 |
RU2542455C2 (ru) | 2015-02-20 |
US20120238605A1 (en) | 2012-09-20 |
JP2013500298A (ja) | 2013-01-07 |
WO2011012527A1 (en) | 2011-02-03 |
CN102470128A (zh) | 2012-05-23 |
BR112012001900A2 (pt) | 2016-03-15 |
RU2012107483A (ru) | 2013-09-10 |
CA2766533A1 (en) | 2011-02-03 |
SG177772A1 (en) | 2012-03-29 |
AU2010277725A1 (en) | 2012-02-16 |
EP2459193A1 (en) | 2012-06-06 |
CR20110674A (es) | 2012-04-17 |
KR20120038982A (ko) | 2012-04-24 |
AU2010277725B2 (en) | 2016-08-18 |
CO6491041A2 (es) | 2012-07-31 |
CL2012000196A1 (es) | 2012-10-05 |
TW201119655A (en) | 2011-06-16 |
NI201200008A (es) | 2012-05-29 |
MX2012000457A (es) | 2012-01-27 |
IL217612A (en) | 2014-08-31 |
PE20121401A1 (es) | 2012-10-25 |
AR077427A1 (es) | 2011-08-24 |
DOP2012000012A (es) | 2012-02-15 |
TWI463982B (zh) | 2014-12-11 |
MA33455B1 (fr) | 2012-07-03 |
US9492437B2 (en) | 2016-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
CL2017000830A1 (es) | Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino. | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
TR201900199T4 (tr) | Oksikodon ve nalokson içeren çabuk salımlı farmasötik bileşimler. | |
EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
PE20141012A1 (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion | |
EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
ECSP12011627A (es) | Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st | |
PA8784901A1 (es) | Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial | |
CL2009000919A1 (es) | Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia. | |
UY33453A (es) | Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina | |
UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
EA201291274A1 (ru) | Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии |